AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
Cancer Chemother. Pharmacol., Sep;70(3):477-86 (2012)
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.
J. Clin. Oncol., May;30(15):1842-8 (2012)
A three-gene expression signature model for risk stratification of patients with neuroblastoma.
Clin. Cancer Res., Apr;18(7):2012-23 (2012)
Mechanisms of CHD5 Inactivation in neuroblastomas.
Clin. Cancer Res., Mar;18(6):1588-97 (2012)
Clinical significance of NTRK family gene expression in neuroblastomas.
Pediatr Blood Cancer., Aug;59(2):226-32 (2012)
Knowing your ABCCs: novel functions of ABCC transporters.
J. Natl. Cancer Inst., Aug;103(16):1207-8 (2011)
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.
Cancer Chemother. Pharmacol., Dec;68(6):1469-75 (2011)
The effect of P75 on Trk receptors in neuroblastomas.
Cancer Lett., Jun;305(1):76-85 (2011)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
Cancer Chemother. Pharmacol., Oct;68(4):1057-65 (2011)
Getting into the AKT.
J. Natl. Cancer Inst., Jun;102(11):747-9 (2010)
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Clin. Cancer Res., Mar;16(5):1478-85 (2010)
Trk receptor expression and inhibition in neuroblastomas.
Clin. Cancer Res., May;15(10):3244-50 (2009)
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
J. Clin. Oncol., Jan;27(2):289-97 (2009)
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
J. Clin. Oncol., Jan;27(2):298-303 (2009)
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature., Oct;455(7215):930-5 (2008)
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
J. Natl. Cancer Inst., Jul;100(13):940-9 (2008)
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
Mol. Cancer Res., May;6(5):735-42 (2008)
Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
J. Clin. Oncol., Feb;26(6):913-8 (2008)
Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.
Oncogene., Jan;27(6):803-10 (2008)
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Cancer Res., Jun;66(12):6050-62 (2006)